INDIANAPOLIS--(BUSINESS WIRE)--Eli Lilly and Company (NYSE: LLY) announced today it has received approval from the FDA to market Reconcile™ (fluoxetine hydrochloride), the first selective serotonin reuptake inhibitor (SSRI) class of antidepressants approved by the FDA for treatment of canine separation anxiety in conjunction with behavior modification training. Reconcile™ is the first Lilly product approved by the FDA for dogs and is now available to U.S. veterinarians.
